8-K: Ligand Pharmaceuticals Exceeds Expectations, Raises Full-Year Guidance After Strong Q3

Ligand Pharmaceuticals reported a strong third quarter in 2024, driven by increased royalty revenue, leading to an upward revision of their full-year revenue and earnings guidance.

Summary

• Ligand Pharmaceuticals announced its financial results for the third quarter and nine months ending September 30, 2024, showcasing significant growth.
• Third-quarter total revenue reached $51.8 million, a 58% increase compared to $32.9 million in the same period of 2023, primarily due to higher royalty revenue and milestone payments.
• Royalty revenue for Q3 2024 was $31.7 million, up 33% from $23.9 million in Q3 2023, driven by the acquisition of QARZIBA and increased sales of FILSPARI.
• The company's Captisol sales were $6.3 million in Q3 2024, down from $8.6 million in Q3 2023 due to order timing.
• Contract revenue and other income surged to $13.8 million in Q3 2024, compared to $0.4 million in Q3 2023, boosted by a $13.5 million milestone payment from the launch of Ohtuvayre.
• Ligand reported a GAAP net loss from continuing operations of $7.2 million, or $0.39 per share, for Q3 2024, compared to a $10.3 million loss, or $0.59 per share, in Q3 2023.
• Core adjusted net income from continuing operations for Q3 2024 was $35.3 million, or $1.84 per diluted share, compared to $18.0 million, or $1.02 per diluted share, in Q3 2023.
• For the nine months ended September 30, 2024, total revenue was $124.3 million, compared to $103.2 million in the same period of 2023.
• Year-to-date royalty revenue was $74.0 million, up from $62.5 million in 2023, and contract revenue was $27.4 million, up from $16.3 million.
• Ligand has increased its full-year 2024 revenue guidance to $160 million $165 million, up from $140 million $157 million, and core adjusted earnings per diluted share to $5.50 $5.70, up from $5.00 $5.50.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the strong financial results, increased guidance, and successful product launches. The company's performance significantly exceeded expectations, and management's comments are optimistic about future growth. The only negative points are minor and do not detract from the overall positive outlook.

Positives

• Ligand experienced a substantial increase in revenue and profitability in the third quarter of 2024.
• The company's royalty revenue grew significantly, driven by the acquisition of QARZIBA and increased sales of FILSPARI.
• Ligand received a significant milestone payment from the commercial launch of Ohtuvayre.
• The company has increased its full-year 2024 financial guidance for both revenue and earnings per share.
• Ligand has a strong cash position with $219.6 million in cash, cash equivalents, and short-term investments.
• Several key portfolio events occurred, including the successful commercial launches of Ohtuvayre and CAPVAXIVE, and the full FDA approval of FILSPARI.
• Ligand's partner, Travere Therapeutics, presented positive data on FILSPARI, showing its clinical benefit in IgAN and potential in FSGS.
• Verona Pharma reported strong initial sales for Ohtuvayre, with October sales exceeding the total third quarter sales.
• Merck's CAPVAXIVE received a positive recommendation from the ACIP for pneumococcal vaccination in adults 50 years of age and older.

Negatives

• Captisol sales decreased in the third quarter of 2024 due to the timing of customer orders.
• Ligand reported a GAAP net loss from continuing operations of $7.2 million for the third quarter of 2024.
• General and administrative expenses increased significantly in both the third quarter and year-to-date periods, primarily due to higher stock-based compensation expenses.
• The company experienced a decrease in GAAP net income from continuing operations for the nine months ended September 30, 2024, due to the impairment of a financial royalty asset and a decrease in investments in Primrose Bio.
• The company had a $15.3 million loss from non-cash fair value adjustments on its Agenus Inc. derivative assets in Q3 2024.

Risks

• Ligand relies on collaborative partners for revenue, and any failure by these partners could impact the company's financial performance.
• The company may not receive expected revenue from Captisol material sales.
• Ligand and its partners may not be able to successfully advance products in their pipelines or receive regulatory approval.
• The company faces competition in acquiring royalties and locating suitable royalties to acquire.
• Ligand is dependent on a single source supplier for Captisol, and any issues with this supplier could impact the company's ability to meet demand.
• Ligand's partners may change their development focus or not execute on their sales and marketing plans.
• The company's products may not be proven safe and efficacious or perform as expected.
• Ligand may not be able to protect its intellectual property.
• Changes in general economic conditions, war, conflict, epidemic diseases, or political events could negatively impact the company.
• Ongoing or future litigation could expose Ligand to significant liabilities.

Future Outlook

Ligand has increased its full-year 2024 financial guidance, expecting total revenue of $160 million to $165 million and core adjusted earnings per diluted share of $5.50 to $5.70. The company anticipates continued growth driven by its portfolio of commercial-stage programs and recently acquired products.

Management Comments

• Todd Davis, CEO of Ligand, stated that the company had one of its best quarters of performance in its history.
• He attributed the success to the strength of the company's growing portfolio of commercial-stage programs.
• He also expressed pleasure in announcing an increase in guidance for the second time this year.
• Davis highlighted key portfolio events, including the successful commercial launches of Ohtuvayre and CAPVAXIVE, and the full FDA approval of FILSPARI, as key drivers of future revenue growth.

Industry Context

Ligand's strong performance and increased guidance reflect positive trends in the biopharmaceutical industry, particularly in the areas of royalty-based business models and the successful commercialization of new therapies. The company's focus on partnering with other pharmaceutical companies to leverage their strengths in late-stage development and commercialization aligns with industry trends towards collaborative drug development. The successful launches of Ohtuvayre and CAPVAXIVE, along with the full FDA approval of FILSPARI, demonstrate the potential for significant revenue growth through strategic partnerships and innovative drug development.

Comparison to Industry Standards

• Ligand's 58% year-over-year revenue growth in Q3 2024 is significantly higher than the average growth rate for many established biopharmaceutical companies, which typically see single-digit or low double-digit growth.
• The 33% increase in royalty revenue is a strong indicator of the success of Ligand's business model, which focuses on acquiring and managing royalty streams from various pharmaceutical products. This is a higher growth rate than many companies that rely solely on product sales.
• The increase in full-year revenue guidance to $160-$165 million suggests that Ligand is outperforming its initial expectations and is on track to achieve significant growth in 2024. This is a positive sign compared to companies that maintain or lower their guidance.
• Ligand's core adjusted net income of $35.3 million in Q3 2024, or $1.84 per diluted share, is a substantial improvement over the previous year, indicating strong operational efficiency and profitability. This is a better result than many companies that are still in the early stages of commercialization.
• The successful commercial launches of Ohtuvayre and CAPVAXIVE, and the full FDA approval of FILSPARI, are significant milestones that position Ligand well for future growth. These achievements are comparable to other successful biopharmaceutical companies that have brought innovative therapies to market.
• Compared to companies like Royalty Pharma (RPRX), which also focuses on royalty streams, Ligand's growth rate in royalty revenue is competitive and demonstrates the effectiveness of its strategy. However, Royalty Pharma has a much larger portfolio and revenue base.
• When compared to companies like Travere Therapeutics (TVTX), which is a partner of Ligand, the success of FILSPARI is a positive sign for both companies. Travere's stock price has also seen positive movement due to the success of FILSPARI.
• Ligand's Captisol technology is a key differentiator, and its use in multiple FDA-approved products, such as Amgen's KYPROLIS and Gilead's VEKLURY, highlights its value. This is a competitive advantage compared to companies that do not have such a platform technology.

Stakeholder Impact

• Shareholders will benefit from the increased revenue, profitability, and positive future outlook, potentially leading to an increase in the company's stock price.
• Employees may benefit from the company's success through potential bonuses and job security.
• Customers of Ligand's partners will benefit from the availability of new and improved therapies.
• Suppliers of Captisol may see increased demand for their products.
• Creditors may view Ligand as a more stable and reliable borrower due to its improved financial performance.

Next Steps

• Ligand will continue to monitor the commercial performance of Ohtuvayre, CAPVAXIVE, and FILSPARI.
• The company will continue to execute its ATM equity offering program.
• Ligand will hold an Investor and Analyst Day in Boston on December 10, 2024.
• Ligand will continue to advance its pipeline and seek new royalty opportunities.
• The company will continue to work with its partners to develop and commercialize new therapies.

Key Dates

Keywords

Ligand Pharmaceuticals, Royalty Revenue, Financial Results, Guidance Increase, Captisol, Ohtuvayre, FILSPARI, QARZIBA, Biopharmaceutical, Drug Development